Patent classifications
A61K35/545
PAR2 MODULATION TO ALTER MYELINATION
Materials and methods for modulating protease activated receptor 2 (PAR2) activity in order to alter myelination or demyelination are provided herein.
PAR2 MODULATION TO ALTER MYELINATION
Materials and methods for modulating protease activated receptor 2 (PAR2) activity in order to alter myelination or demyelination are provided herein.
METHODS TO DIFFERENTIATE STEM CELLS INTO HORMONE-PRODUCING CELLS
Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.
METHODS TO DIFFERENTIATE STEM CELLS INTO HORMONE-PRODUCING CELLS
Methods are described for differentiating stem and post-natal cells into sex hormone-producing cells that can be administered to a patient autologously or allogeneically in order to maintain in balance, or rebalance, their hypothalamic-pituitary-gonadal (HPG) axis.
ENGINEERED MULTICELLULAR ORGANISMS
Disclosed are engineered multicellular organisms. Also disclosed are systems and methods for designing, preparing, and utilizing the engineered multicellular organisms.
ENGINEERED MULTICELLULAR ORGANISMS
Disclosed are engineered multicellular organisms. Also disclosed are systems and methods for designing, preparing, and utilizing the engineered multicellular organisms.
Zinc Finger Protein Transcription Factors for Treatment of Prion Disease
The present disclosure provides zinc finger fusion proteins that inhibit expression of the prion gene in the nervous system, and methods of using the proteins to treat prion disease.
METHOD FOR FREEZING NEURAL CELLS
Provided is a method for freezing a cell aggregate including neural cells. provided is a method for freezing a cell aggregate including neural cells and having a three-dimensional structure, which comprises following steps (1) and (2): (1) contacting a cell aggregate including neural cells and having a three-dimensional structure with a preservation solution at 0° C. to 30° C. prior to freezing to prepare a preservation solution-soaked cell aggregate; and (2) cooling the preservation solution-soaked cell aggregate obtained in step (1) from a temperature at least about 5° C. higher than the freezing point of the preservation solution to a temperature about 5° C. lower than the freezing point at an average cooling speed of 2 to 7° C./min to freeze the cell aggregate.
COMPOSITIONS AND METHODS FOR GENERATION OF SINOATRIAL NODE-LIKE CELLS AND THEIR USE IN DRUG DISCOVERY
Provided are methods for producing population of cells enriched for cells exhibiting sinoatrial node like characteristics. The cells can be produced from human pluripotent cells. Also provided are methods for using the SAN-like cells for identifying agents that can mitigate drug-induced cardiac toxicity. Also provided is a method for mitigating drug induced cardiotoxicity comprising administering to a subject an effective amount of physcion or a derivative thereof.
Chimeric antigen receptor and use thereof
Disclosed herein is a novel chimeric antigen receptor and use thereof. The novel chimeric antigen receptor consists of a signal peptide, an antigen binding domain, a transmembrane region, and an intracellular signal domain, and comprises a 4-1BB signal peptide and/or a 4-1BB molecular transmembrane region. Nucleic acid sequences of various chimeric antigen receptors are separated and purified and provided is a chimeric antigen receptor and a CAR-T cell which are specific for a CD19 malignant tumor antigen. In the malignant tumor killing test of hematological cell lines, the ability of immune cells to target and recognize tumor cells is significantly enhanced, and the killing activity against tumor cells is also enhanced.